Bentley Pharmaceuticals (BNT) Receives Spanish Approval for Generic Casodex
More News related to AZN
- Notable Analyst Rating Changes 11/09: RSH, ANF, NOC, ADBE, HERO Upgraded; RIMM, RHT, GPS, AZN, SGY Downgraded
- RBS Upgrades AstraZeneca (AZN) to Buy
- J.P. Morgan Downgrades AstraZeneca (AZN) to Underweight
- Emerging Stock Report Initiates Independent Research Coverage On Human Genome Sciences
- Widespread Generic Erosion of Atypical Antipsychotics Will Cause the Bipolar Disorder Drug Market to Decline By More Than $1 Billion Through 2018
More News related to BNT
- Notable Mergers and Acquisitions of the Day 7/23 (CSCO, BNT/TEVA, PHLY)
- Bentley (BNT) Shareholders Approve Merger with TEVA Pharma (TEVA)
- Bentley Pharma (BNT) Announces Adjustment To Teva (TEVA) Merger Price
- Bentley Pharmaceuticals (BNT) Misses Q1 EPS Views
- Unusual 11 Mid-Day Movers 3/31: ANST, VRTX, BNT, XJT Higher; SGP, FRP, TMA, MRK Lower
More News related to FDA
- Teva Pharma (TEVA) Gets Final U.S. FDA Approval for Generic Prevacid
- Mylan (MYL) Gets FDA Ok for Generic Prevacid
Bentley Pharmaceuticals, Inc. (NYSE: BNT) announced that its subsidiaries, Laboratorios Belmac and Laboratorios Davur, have received product approvals of bicalutamide from the Spanish Ministry of Health.
Bicalutamide is the generic equivalent to AstraZeneca Pharmaceuticals' (NYSE: AZN) Casodex. Bicalutamide is prescribed as a treatment to prevent the growth of prostate cancer by blocking the effects of androgens on the cancer cells. The treatment is a non-steroidal, anti-androgenic product orally administered as a 50 mg. tablet.
Related Categories
FDAStocks Mentioned
-0.03
+0.00Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
